Your browser is no longer supported. Please, upgrade your browser.
EIDX Eidos Therapeutics, Inc. monthly Stock Chart
EIDX [NASD]
Eidos Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.65 Insider Own1.00% Shs Outstand38.39M Perf Week12.08%
Market Cap3.43B Forward P/E- EPS next Y-3.35 Insider Trans-16.57% Shs Float12.61M Perf Month24.91%
Income-100.80M PEG- EPS next Q-0.79 Inst Own32.20% Short Float5.18% Perf Quarter113.47%
Sales0.10M P/S34299.00 EPS this Y44.60% Inst Trans-0.98% Short Ratio3.06 Perf Half Y84.05%
Book/sh3.20 P/B28.13 EPS next Y-14.30% ROA-53.00% Target Price62.83 Perf Year61.41%
Cash/sh3.87 P/C23.29 EPS next 5Y28.00% ROE-65.20% 52W Range28.39 - 89.00 Perf YTD56.82%
Dividend- P/FCF- EPS past 5Y- ROI-21.60% 52W High1.13% Beta-
Dividend %- Quick Ratio11.10 Sales past 5Y- Gross Margin- 52W Low217.01% ATR2.96
Employees70 Current Ratio11.10 Sales Q/Q-99.60% Oper. Margin- RSI (14)82.12 Volatility3.60% 3.93%
OptionableYes Debt/Eq0.14 EPS Q/Q-527.70% Profit Margin- Rel Volume0.20 Prev Close88.71
ShortableYes LT Debt/Eq0.14 Earnings- Payout- Avg Volume213.60K Price90.00
Recom3.10 SMA2016.05% SMA5030.04% SMA20073.85% Volume42,420 Change1.45%
Nov-18-20Downgrade BTIG Research Buy → Neutral
Sep-22-20Downgrade Guggenheim Buy → Neutral
Sep-08-20Initiated Citigroup Buy $80
May-14-20Downgrade JP Morgan Overweight → Neutral $58 → $50
Apr-01-20Resumed BofA/Merrill Neutral $51
Feb-20-20Initiated Guggenheim Buy $66
Feb-18-20Downgrade Barclays Equal Weight → Underweight $45
Nov-01-19Downgrade Barclays Overweight → Equal Weight $37 → $45
Jul-22-19Initiated Piper Jaffray Overweight $55
Feb-27-19Upgrade JP Morgan Neutral → Overweight
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Oct-31-18Initiated ROTH Capital Buy
Jul-16-18Initiated JP Morgan Overweight $36
Jul-16-18Initiated BofA/Merrill Neutral $24
Jul-16-18Initiated Barclays Overweight $32
Nov-25-20 10:32PM  
08:01AM  
Nov-23-20 08:31PM  
Nov-20-20 09:34PM  
08:30PM  
Nov-19-20 06:36PM  
Nov-13-20 10:35PM  
08:00PM  
07:01PM  
12:30PM  
08:01AM  
Nov-12-20 01:40PM  
Nov-09-20 06:15PM  
Nov-07-20 07:49PM  
Nov-06-20 11:27PM  
08:00PM  
08:01AM  
Nov-05-20 10:53AM  
07:30AM  
Nov-03-20 10:39AM  
Oct-31-20 06:57PM  
Oct-30-20 09:41PM  
03:31PM  
Oct-29-20 04:30PM  
Oct-27-20 10:15AM  
Oct-26-20 06:54PM  
01:37PM  
Oct-24-20 02:10PM  
Oct-23-20 04:44PM  
Oct-22-20 08:37PM  
07:17PM  
05:00PM  
Oct-21-20 10:20PM  
06:48PM  
08:25AM  
Oct-20-20 06:00PM  
03:12PM  
10:00AM  
Oct-19-20 03:24PM  
09:10AM  
Oct-17-20 02:05PM  
Oct-15-20 04:23PM  
12:07PM  
10:45AM  
Oct-14-20 07:00PM  
06:52PM  
03:09PM  
01:14PM  
09:45AM  
Oct-13-20 08:20PM  
12:40PM  
08:03AM  
Oct-12-20 07:40PM  
09:15AM  
08:00AM  
Oct-09-20 06:23PM  
02:38PM  
11:19AM  
09:00AM  
08:01AM  
Oct-08-20 04:00PM  
09:00AM  
Oct-07-20 08:05PM  
06:30PM  
05:36PM  
10:10AM  
08:56AM  
08:30AM  
Oct-06-20 06:50PM  
01:28PM  
12:53PM  
08:48AM  
Oct-05-20 10:29PM  
09:00PM  
06:50PM  
05:10PM  
04:21PM  
01:46PM  
12:05PM  
09:23AM  
09:06AM  
07:21AM  
07:04AM  
Sep-08-20 10:10AM  
Aug-07-20 04:30PM  
Aug-06-20 04:30PM  
Jul-05-20 03:05PM  
Jul-01-20 08:38AM  
Jun-10-20 09:13PM  
May-08-20 04:30PM  
Apr-07-20 05:19PM  
Mar-31-20 04:52PM  
Mar-19-20 10:29AM  
Feb-26-20 04:30PM  
Feb-05-20 09:15AM  
Dec-12-19 03:14PM  
Dec-06-19 08:00AM  
Nov-18-19 09:00AM  
Nov-16-19 07:28PM  
05:30PM  
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Turtle CameronChief Business OfficerNov 11Sale74.5113,410999,22752,121Nov 13 05:00 PM
Valle FrancoSenior Vice President, FinanceNov 09Option Exercise7.241,62311,7511,623Nov 10 04:05 PM
Valle FrancoSenior Vice President, FinanceNov 09Sale74.931,623121,6090Nov 10 04:05 PM
Turtle CameronChief Business OfficerNov 02Option Exercise14.477,500108,50078,031Nov 03 04:05 PM
Turtle CameronChief Business OfficerNov 02Sale70.7212,500883,95465,531Nov 03 04:05 PM
Sinha UmaChief Scientific OfficerOct 29Sale72.425,000362,099321,525Oct 30 04:55 PM
Valle FrancoSenior Vice President, FinanceOct 08Option Exercise7.245,19937,6415,199Oct 09 05:23 PM
Valle FrancoSenior Vice President, FinanceOct 08Sale74.855,199389,1510Oct 09 05:23 PM
Valle FrancoSenior Vice President, FinanceOct 07Option Exercise7.245,00036,2005,444Oct 09 05:23 PM
Valle FrancoSenior Vice President, FinanceOct 07Sale75.085,444408,7480Oct 09 05:23 PM
Sinha UmaChief Scientific OfficerOct 01Sale52.354,831252,923326,525Oct 02 07:43 PM
Sinha UmaChief Scientific OfficerSep 30Sale52.031698,794331,356Oct 02 07:43 PM
Fox Jonathan CSee RemarksSep 17Sale50.165,767289,259377,673Sep 18 04:06 PM
Fox Jonathan CSee RemarksSep 16Sale50.163,122156,610383,440Sep 16 06:35 PM
Fox Jonathan CSee RemarksSep 15Sale50.061,00050,064386,562Sep 16 06:35 PM
Fox Jonathan CSee RemarksSep 14Sale50.001115,550387,562Sep 16 06:35 PM
Turtle CameronChief Business OfficerSep 10Option Exercise17.002,50042,50073,031Sep 11 04:05 PM
Turtle CameronChief Business OfficerSep 10Sale47.002,500117,50070,531Sep 11 04:05 PM
Turtle CameronChief Business OfficerAug 03Option Exercise13.205,00066,00080,531Aug 05 07:45 PM
Turtle CameronChief Business OfficerAug 03Sale39.9410,000399,45070,531Aug 05 07:45 PM
Fox Jonathan CSee RemarksJul 07Sale50.005,000250,000387,673Jul 09 04:05 PM